Measuring Enduring Worsening Of Multiple Sclerosis In The CombiRx Study (S34.007)

CONCLUSIONS: This study demonstrates that of the various measures of worsening, 6 month confirmed increase of EDSS occurred more frequently than the other metrics, but was less durable than some. The 1+1 assessment produced the greatest percentage worsening from baseline and was the most durable metric. Ever reaching EDSS 6 had similarly good durability and second best percentage ending study above baseline. Once correlated with relapse activity, these assessments may serve as a basis for defining secondary progressive MS.Study Supported by: NIH/NINDS NS045719Disclosure: Dr. Lublin has received personal compensation for activities with Biogen Idec, EMD Serono, Inc., Novartis, Teva Neuroscience, Actelion, Sanofi-Aventis Pharmaceuticals, Inc., Acorda Therapeutis, Questcor, Roche, Genentech, Inc., Celgene, Johnson & Johnson, Revalesio, Coronado Bioscience, Genzyme Corporation, MedImmune, Bristol-Myers Squibb Company, Xenoport, Receptos, Forward Pharma, and Osmotica. Dr. Lublin has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Diseases. Dr. Lublin has received research support from Acorda Therapeutics, Inc., Biogen Idec, Novartis, Teva Neuroscience, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., Celgene, National Institutes of Health, and the National Multiple Sclerosis Society. Dr. Cofield has received personal compensation for activities with Teva Neuroscience, Orthotech Biotech, the American Academy for Orthopedic Su...
Source: Neurology - Category: Neurology Authors: Tags: MS and CNS Inflammatory Disease: Risk Factors for Multiple Sclerosis Disease and Course Source Type: research